论文部分内容阅读
目的探讨米非司酮治疗围绝经期功能性子宫出血的临床疗效。方法将64例围绝经期功能性子宫出血患者随机分为研究组和对照组,研究组采用米非司酮进行治疗,对照组采用安宫黄体酮进行治疗,比较两组患者的子宫大小、内膜厚度、血清激素水平及不良反应。结果研究组子宫前后径为(4.6±1.3)cm,子宫横径为(5.8±1.1)cm,子宫体积为(65.2±3.2)cm3,子宫内膜厚度为(2.8±0.3)cm、促卵泡生成素为(8.4±2.2)U/L,黄体生成素为(6.4±1.5)U/L,孕激素为(1.7±1.6)nmol/L,雌二醇为(108.3±1.2)pmol/L,不良反应总发生率为9.375%,研究组显著优于对照组(P<0.05)。结论米非司酮治疗围绝经期功能性子宫出血疗效确切,安全可靠,值得在临床广泛推广。
Objective To investigate the clinical efficacy of mifepristone in the treatment of functional uterine bleeding during perimenopausal period. Methods Sixty-four patients with functional uterine bleeding during the climacteric period were randomly divided into study group and control group. The study group was treated with mifepristone, the control group was given progesterone acetate for treatment. The uterus size, Membrane thickness, serum hormone levels and adverse reactions. Results The anteroposterior diameter of the uterus in the study group was (4.6 ± 1.3) cm, the mean uterine diameter was (5.8 ± 1.1) cm, the uterus volume was (65.2 ± 3.2) cm3 and the thickness of the endometrium was (2.8 ± 0.3) (8.4 ± 2.2) U / L, (6.4 ± 1.5) U / L for luteinizing hormone, (1.7 ± 1.6) nmol / L for progestin and (108.3 ± 1.2) pmol / L for estradiol, The overall response rate was 9.375%, which was significantly better in the study group than in the control group (P <0.05). Conclusion The efficacy of mifepristone in treating peri-menopausal dysfunctional uterine bleeding is safe, reliable and worthy of wide application in clinic.